Semax

A heptapeptide developed in Russia from an ACTH fragment — used as a nootropic and for stroke recovery in Russian clinical practice.

Why it matters

Semax is a synthetic peptide based on a fragment of adrenocorticotropic hormone (ACTH 4-10). It increases BDNF, modulates dopamine and serotonin, and is approved in Russia for cognitive impairment and stroke recovery. In Western markets it operates in the research-peptide category.

In practice

Typical use is intranasal at 250–600mcg per administration. Effects are reported acutely (within an hour) — alertness, mood elevation, reduced perception of fatigue.

Common confusion

Semax is sometimes compared to modafinil. The mechanism is entirely different; the subjective category overlap is partial.

This glossary entry is editorial content reviewed against primary sources. It is not medical advice. See our Editorial Policy.